**A Population Pharmacokinetic Model Based on HPTN 077 of Long-acting Injectable Cabotegravir for HIV PrEP**

Yifan Yu1, Kristin L. Bigos2,3,4, Mark A. Marzinke2,5, Raphael J. Landovitz6, Marybeth McCauley7, Susan Ford8, Craig W. Hendrix2,4,9, Robert R. Bies1, Ethel D. Weld2,4,9, the HPTN 077 Study Team

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1 State University of New York at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA

2 The Johns Hopkins University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Baltimore, MD, USA

3 The Johns Hopkins University School of Medicine, Department of Psychiatry, Baltimore, MD, USA

4 The Johns Hopkins University School of Medicine, Department of Pharmacology and Molecular Sciences, Baltimore, MD, USA

5 The Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, MD, USA

6 The University of California, Los Angeles, Center for Clinical AIDS Research and Education, Los Angeles, CA, USA

7 FHI 360, Durham, NC, USA

8 GlaxoSmithKline, Research Triangle Park, NC, USA

9 The Johns Hopkins University School of Medicine, Department of Medicine, Division of Infectious Diseases, Baltimore, MD, USA

**Abstract**

*Background* Cabotegravir delivered as a long-acting intramuscular injection has shown superior efficacy to oral tenofovir-emtricitabine as pre-exposure prophylaxis (PrEP) for HIV. Cabotegravir pharmacokinetics (PK), like those of other long-acting depot preparations, exhibit variability between individuals and between injection occasions. *Aim* To describe the population pharmacokinetics of long-acting cabotegravir (CAB-LA). *Methods* Using available PK measurements from 133 participants in the HIV Prevention Trials Network (HPTN) 077 trial, we analyzed CAB-LA PK data using nonlinear mixed-effects modeling to develop a population PK model. *Results* A two-compartment model with first order absorption best described the CAB-LA PK. The analysis identified between-occasional variability (BOV, i.e., differences in PK within one individual from one injection to the next) as a significant covariate affecting the absorption rate. Sex and body weight were identified as significant covariates influencing the absorption rate and apparent clearance of CAB-LA after intramuscular injection at various doses and frequencies. *Conclusion* The public availability of this model will facilitate and enable a wide variety of future clinically relevant simulations to inform the optimal use of CAB-LA.

**Introduction**

The significant preventive efficacy of oral HIV pre-exposure prophylaxis (PrEP) has been undermined by the reality of incomplete adherence to daily oral medications, in both the real world and clinical trials context.1-3 The advent of novel, less-frequent dosing approaches for biomedical prevention offers the possibility of improved adherence and therefore improved protection against HIV.4 Cabotegravir, a compound closely chemically related to dolutegravir, is an integrase strand transfer inhibitor (INSTI) with potent activity against HIV *in vitro* and *in vivo* and characteristics that support its long-acting delivery as an extended-release injectable suspension.5,6

Cabotegravir pharmacokinetics (PK) differ according to formulation. When orally administered, it exhibits linear PK with multiple dose administration, with immediate absorption and low inter-individual variability in PK parameters, including rate of absorption (ka) and rate of clearance.7 When delivered as a long-acting injectable suspension, cabotegravir (CAB-LA) exhibits “flip-flop” PK that is defined by its absorption rate rather than its elimination, with a high degree of inter-individual variability.8,9

Dosing frequency of injectable CAB-LA has evolved as human data has accrued. The ÉCLAIR trial of CAB-LA among HIV-negative men administered a dose of 800 mg IM every 12 weeks, which had been predicted from modelling of human data following oral CAB (CAB n=288) and CAB LA (n=93) administration, including 9 healthy participants who received 2 quarterly 800mg doses.10 However, the concentration target (set at 4x protein-adjusted [PA]-IC90, or 0.664µg/mL), as determined to be relevant for protection in NHP SHIV challenge studies, was achieved in only one-third of ÉCLAIR participants.11 Modeling indicated that both (1) reducing the dose and dose frequency to 600 mg IM every 8 weeks and (2) adding a “loading dose” by giving an earlier second dose 4-weeks after the first dose (before starting every 8 weeks dosing thereafter) would be more likely to achieve target plasma concentrations in most people. The Phase 2a HIV Prevention Trials Network (HPTN) 077 study, which characterized the safety and PK of CAB-LA in 199 healthy adults, was already in progress using a dose of 800 mg CAB-LA IM q 12 weeks for 3 injections total (Cohort I), when the ÉCLAIR modeling data became available. Consequently, the HPTN 077 clinical trial was amended to include a sequentially enrolled second cohort using 600mg CAB-LA IM q 8weeks for 5 injections total, including the initial two injections separated by 4 weeks (Cohort 2).12,13

“Tail-phase” PK after the terminal intramuscular (IM) injection was examined in 177 of the HPTN 077 participants, and a sex-based divergence in PK was observed (sex at birth, hereafter referred to as sex). The median time between the last IM injection and cabotegravir concentration declining to non-quantifiable concentrations (< 0.025 µg/mL) was significantly longer in women, 67.3 weeks (IQR 29.1-89.6; range 17.7-225.5), compared to 43.7 weeks (interquartile range (IQR) 31.1-66.6; range 20.4-152.5) for men (p=0.0003).14 Accordingly, the apparent cabotegravir terminal half-life (t1/2app) was 1.33-fold longer (95% CI 1.06-1.68; p=0·014) in women than in men. The t1/2app was also longer for participants with greater than or equal to median body-mass index (BMI) than those below median BMI (1·31-fold higher, 95% CI 1.06-1.63; p=0·015). These two factors, however, only explained 10% of the elimination-phase PK variability of CAB-LA; other significant contributors to its PK variability are as yet undefined. There may be a difference in CAB-LA PK for any given dose depending on whether depot location is subcutaneous or intramuscular; in a companion tissue PK study to HPTN 077, when location of injection depot was visualized with magnetic resonance imaging (MRI), recipients with subcutaneous depot locations had lower peak concentrations, longer terminal half-life, and higher area under the concentration curve (AUC) than individuals whose depot location was intramuscular.15

Large double-blind, double-dummy randomized controlled phase 3 efficacy trials followed, which compared the HIV preventive efficacy of CAB-LA to that of oral tenofovir disoproxil fumarate-emtricitabine, and found superiority in HIV preventive efficacy of CAB-LA in both cisgender women (HPTN 084) and cisgender men and transgender women who have sex with men (HPTN 083).16,17 PK-PD relationships underlying this finding remain incompletely understood, partially due to the high rate of efficacy. Four incident cases of HIV occurred in participants during the blinded phase of the HPTN 083 study, despite mostly on time injections and cabotegravir concentrations above the 4x PA-IC90 target at 95% of visits; prior to detection of viral infection, one of those cases fell below 4x PA-IC90 once, two cases fell below 8x PA-IC90 once, and one never fell below 8x PA-IC90.18 The timing of these concentration dips occurred between the first and second injection in three out of the four cases. In HPTN 084, there was one incident case of HIV that occurred during the injection phase of the study; several of that participant’s injections were administered late, and drug concentrations were below target concentrations at the first HIV positive visit. It would be advantageous to understand, based on modelling of the pharmacokinetic data from HPTN 077, what alternative dosing strategies could result in safely achieving the maximal proportion of individuals above whatever target protective concentration is eventually established from PK-PD analysis of HPTN 083 and HPTN 084 (tentatively, >8x PA-IC90). Alternative strategies could include changes in dosages or intervals based on individual characteristics (e.g., sex or weight/BMI), reconsideration of an oral lead-in or oral dosing overlap (just as likely to be complicated by the adherence challenges of oral dosing as when oral dosing precedes injection), or more frequent early IM dosing as a load. Strategies accounting for the impact of occasional delayed injections or the occasional anomalous instance of an injection with lower than expected exposures (as observed in several of the HPTN 083/084 breakthrough cases of HIV) could help maintain protective concentrations. Finally, simulations to support a precision medicine-based individualized therapeutic drug monitoring approach could potentially play a role one day in optimizing CAB-LA dosing for HIV prevention.

While the manufacturer of CAB-LA (ViiV Healthcare) has developed and presented a population PK model for the drug based on a large and rich dataset of available PK data across many clinical studies, parameters such as between subject variability or between occasion variability are not available, and uncertainty in parameter estimates is not completely characterized.19,20 Simulations based on that model have been performed, for example, in the HIV treatment context, where CAB LA is dosed per FDA label instructions every 4 weeks along with long-acting rilpivirine (RPV LA). Those simulations have supported resuming CAB LA and RPV LA without a loading dose for treatment delays of less than 1 month, and reloading with a 1.5x higher than usual dose for treatment interruptions greater than 1 month. Simulations in the setting of PrEP and every 2 month dosing overall have also supported reloading (with usual dose once a month for two injections followed by every 2 months thereafter) in the setting of unplanned dose interruptions of > 8 weeks. 21,22

As the HPTN 077 study offers rich multi-dose pharmacokinetic data in both men and women given varying dosing approaches (600 mg q8 weeks and 800 mg q 12 weeks) and includes PK tail data, it is an important data source to inform a population pharmacokinetic model of CAB-LA, which can potentially answer key questions about the use of CAB-LA as PrEP. Therefore, we aimed to develop population PK model that adequately describes the HPTN 077 data specifically, from which future clinically important simulations can be performed to model the adequacy of alternative dosing strategies in various subgroups, support future clinical trial design, and overall contribute to the optimization of CAB-LA as PrEP.

**Methods**

*Clinical Trial*

Methods and findings of the parent HPTN 077 study have been previously published.13,14 Out of a total of 199 participants in the parent HPTN 077 trial, 177 received at least one injection, of whom 151 had PK data available. Of those 151, one individual did not have an initial plasma concentration before the first injection, and 17 individuals only had PK measurements after oral formulation; these 18 were removed from the NONMEM dataset, giving a total of 133 individuals included in this analysis. Participants first received 30 mg cabotegravir by mouth daily for an oral lead-in period of 28 days; participants without safety concerns during oral lead-in and at least 75% adherence by pill count continued on to receive injections. Participants in Cohort 1 received injections of CAB LA 800 mg IM every 12 weeks for 3 injection cycles, administered as two split 400 mg (2 mL) IM injections in the gluteal muscle. Participants in Cohort 2 received two injections of CAB LA 600 mg (3 mL) IM separated by 4 weeks, followed by 600 mg every 8 weeks for 3 additional injections thereafter.

*Model development*

We analyzed CAB-LA PK data from HPTN 077 using nonlinear mixed-effects modeling with NONMEM® (7.3.0) to develop a population pharmacokinetic model. The ADVAN13 subroutine and first-order conditional estimation method with interaction were used. We used RStudio (version 1.4) for dataset preparation, data visualization, and diagnostic plot generation. A likelihood-based approach (Method 3) was used to handle measurements below the lower limit of quantitation at 0.025 µg/mL.23 The model-building process was guided by changes in the NONMEM objective function value and diagnostic plots. An alpha threshold of 0.05 was set for the model improvement threshold (corresponding to a change in NONMEM objective function value (OFV) of 3.84 units for 1 degree of freedom).

**Structural model**

One-compartment and two-compartment models were explored for CAB-LA. The parameters used to describe the pharmacokinetics of cabotegravir include apparent clearance (CL/F), apparent central volume (Vc/F), apparent peripheral volume (Vp/F), apparent intercompartmental clearance (Q/F), and first-order absorption rate (Ka). Since all the patients received a 4-week oral lead-in, the concentration measurement for each individual before the first injection dose was used as the initial condition of the differential equations.

**Random effect model**

Inter-individual variability (IIV) with a log-normal distribution was supported for all the PK parameters:

Where the P represents the individual value of the parameter P, the represents the typical value of the parameter P, and the denotes the IIV, which is assumed to have a normal distribution with mean equal to 0 and variance equal to .

Proportional, additive and a combined additive and proportional error models were tested to describe the residual unexplained variability:

Where the represent the observed concentration of subject i at time j, the represent the predicted concentration, and represent the proportional and additive error. They were assumed to be normally distributed, with mean = 0 and variances of and

For the parameters Ka and CL, the between occasion variability (BOV) was evaluated as an additional level of random effect:

**Covariate model**

Once the base model was established, covariates including body weight, BMI, sex, and age were first explored by visualization. We tested the potential covariate relationship of body weight, sex, and age on CL, Q, V2 and V3, and bodyweight, BMI, sex, age on Ka. Potential covariate relationships identified by the exploratory visualization were then studied using stepwise forward selection and backward elimination. For the forward selection, a decrease of the OFV more than 3.84 was considered significant (p<0.05). For the backward elimination, an increase of OFV more than 6.63 was considered significant (p<0.01). The continuous covariates were modeled using this equation:

Where the denotes the individual typical value of parameter, denotes the individual covariate, and denotes the population median of the covariate. The categorical covariate, sex, was modeled using this equation:

To determine relevant predictors of BOV, the distribution of standard deviations for the etas was visualized by the following covariates: sex, race, and BMI (obese versus non-obese, using a cut-off of 30 kg/m2). These were compared using a Welch 2-sample t-test with shared variance (for BMI and sex) and one-way ANOVA (for race.) 12 individuals who received only one injection were excluded from this analysis. A unique BOV distribution was also tested for the sex covariate affecting Ka.

**Results**

Concentration-time plots by sex are shown, for visualization, for the two cohorts in Figure 1. Demographics by cohort, summarized in Table 1, are notable for a study population that was 67% female and 41% Black. The model building process is summarized in Table 2. A two-compartment model with first order absorption best described the CAB-LA PK. A schema of the final structural model is shown in Figure 2. The PK of CAB-LA was best characterized by the following differential equations:

Here, represents the amount of drug in the depot, represents the concentration in the central compartment, and represents the concentration in the peripheral compartment.

In the final model, the between-participant variability was supported for all the parameters, and the between-occasional variability was supported for Ka when evaluated as an additional level of random effect. Covariate relationships of sex at birth on Ka and body weight on CL were identified. A unique BOV distribution for Ka by sex, BMI (Obese/others) and race was not significantly different across these covariates. The first-order absorption rate constant of female sex was estimated to be 0.0003 h-1, which is 40% less than male sex (0.0005 h-1). The relationship between body weight and clearance was described by the classic allometric relationship, with the exponent fixed to 0.75. Estimated values of PK parameters are summarized in Table 3. According to the diagnostic plots (shown in Figure 3), the PK profile of CAB-LA was well characterized.

**Discussion**

To better understand the absorption and drug disposition of CAB-LA, we developed a population pharmacokinetic model based on data from HIV negative research participants in the HPTN 077 trial. We found that a two-compartment model with first-order absorption provided the best fit for the data, which is consistent with a previous study.19 We tested several covariates (including weight, BMI, sex, and age) for their influence on PK parameters. In the final model, we identified weight as a significant covariate affecting the apparent clearance, and sex as a significant influence on Ka. According to the final estimate, the first-order absorption rate constant in women was 40% lower than in men. (Figure 4). As has been previously described, CAB-LA exhibits the flip-flop kinetics typical of long-acting injectables, where the apparent terminal half-life is governed by the absorption rate constant, Ka.24 In a previous single-dose study, there was a non-statistically significant trend of higher CAB-LA plasma exposures in female compared to male participants after subcutaneous administration and higher plasma exposures in male participants after a split IM injection.8 Sex-based differences in absorption rate may reflect different skin-to-muscle depth or different fat content and distribution within tissues at the site of injection depot. In the previous PK analysis of this CAB-LA data from HPTN 077, BMI above the median, in addition to female sex, was identified as a covariate significantly associated with lower Ka.14 However, in our analysis, this covariate relationship was not detected, as BMI did not add statistically to the characterization of the Ka once sex was incorporated. Because sex had a stronger effect, it was included first in the modelling sequence.

Comparing our results to those of other studies, the population CL/F estimated in our study (0.148 L/h) was similar to values from a previous study using data from HIV negative adult participants and participants living with HIV-1 (0.175 L/h) as well as the full population PK model for CAB LA (0.151 L/h).19,20 Body weight was found to be a significant predictor of apparent clearance (CL/F). In addition, the central and peripheral volume of distribution (estimated V2/F and V3/F; 7.84 L and 6.99 L, respectively) were slightly higher than previously reported values (7.70 L and 3.14 L).25

In the final model, the between-occasion variability (BOV) was attributable to differences in absorption rate (Ka) from one injection occasion to the next. The estimated variability from occasion to occasion on the absorption rate (Ka) was 38.5%. This variability is relatively large, but reasonable, for a long-acting injectable formulation, since the absorption of the injectable formulation of cabotegravir is influenced by the depth, vascularity, lymphatics, and fat content of the injection site, as is true of many other long-acting depot formulations, including paloperidone .15,26-28 For comparison, in one population PK study of paliperidone, the BOV on clearance, volume of distribution, and dose fraction in the central compartment were 26% CV, 14% CV, and 0.07 SD, respectively.28 In our examination of whether BOV varied according to characteristics such as sex, race, and BMI, we found no significant associations between any of these characteristics and BOV. Thus, the variability in exposures from one administration to the next was not completely or satisfactorily explained by variable locus of depot according to different fat distribution in women and men. A vulnerability to lower cabotegravir exposures early on in dose administration (i.e., between the first and second injections, as seen in HPTN 083 and 084) could mean various overlap and loading strategies could be productively explored with simulations, to get around the BOV factor with adequate dosing “cushion”. Regardless, a better understanding of variables influencing BOV are key to truly personalized dosing, but they have not yet emerged from the data. Currently, long-acting injectable cabotegravir is only recommended for injection in the gluteal region, but there is interest in expanding injection site options, such as anterior thigh self-injection, and it is possible that these absorption kinetics will differ according to body site where injection is administered, due to different fat-to-muscle relationships and other as yet unidentified variables.12

In general, the role of personalized dosing for CAB-LA as PrEP remains unclear, in part because the concentration-response relationship has not been established in this PrEP setting due to rarity of cases of HIV infection during active injection phases of pivotal trials. A component of individualized dosing based on PK measurements could have important implications for efficacy as well as participant-important outcomes like satisfaction and adherence, particularly if it enables a more convenient extended dosing interval in some people, given the considerable variability between individuals and between occasions within the same individual. The publication of this population PK model creates a foundation for asking these important questions, in the populations who will most benefit from this long-acting strategy.

**Conclusions**

A two-compartment model with first order absorption best described the pharmacokinetics of CAB-LA. The population pharmacokinetic analysis identified between-occasional variability (i.e., differences in PK within one individual from one injection to the next) as a significant covariate on the absorption rate. Sex and body weight were identified as significant covariates influencing the absorption rate and apparent clearance of CAB-LA after intramuscular injection at various doses and frequencies. The public availability of this model will facilitate and enable a wide variety of future clinically relevant simulations to inform the optimal use of CAB-LA.

**Funding**

The authors gratefully acknowledge the funding support from the HPTN and NIH for the original HPTN 077, study which provided the data for this secondary analysis. EDW receives funding from the NIH NIAID—award number K23 AI165290-01. CWH reports receiving research contract funding and scientific advisory board honorarium and/or travel support from ViiV Healthcare, Gilead, and Merck, and is the founder of PRIÖNDE Biopharma, LLC. All potential conflicts for CWH, EDW and KB managed by Johns Hopkins University.

**Conflict of Interest Statement**

Dr. Ford is an employee of ViiV/GSK.

**References**

**1.** Dimitrov DT, BR MA, Donnell D. PrEP adherence patterns strongly impact individual HIV risk and observed efficacy in randomized clinical trials. J Acquir Immune Defic Syndr.2016.

**2.** Wheeler DP, Fields SD, Beauchamp G, et al. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc.2019;22(2):e25223.

**3.** Hebel S, Kahn-Woods E, Malone-Thomas S, et al. Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings. J Acquir Immune Defic Syndr.2020;85(4):454-457.

**4.** Gulick RM, Flexner C. Long-Acting HIV Drugs for Treatment and Prevention. Annu Rev Med.2019;70:137-150.

**5.** Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection. Antimicrobial Agents and Chemotherapy.2015;59(1):397-406.

**6.** Bowers GD, Culp A, Reese MJ, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica.2016;46(2):147-162.

**7.** Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials.2013;14(5):192-203.

**8.** Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr.2014;67(5):481-486.

**9.** Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr.2014;67(5):487-492.

**10.** Ford S, Chiu, J, Lovern, M, et al. Population PK approach to predict cabotegravir (CAB, GSK1265744) long-acting injectable doses for phase 2b (Ph2b). ICAAC 2014. September 5-9, 2014. Washington, DC. Abstract H-645. ICAAC. Washington, D.C.2014.

**11.** Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV.2017;4(8):e331-e340.

**12.** Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLOS Medicine.2018;15(11):e1002690.

**13.** Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med.2018;15(11):e1002690.

**14.** Landovitz RJ, Li S, Eron JJ, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV.2020;7(7):e472-e481.

**15.** Jucker BM, Fuchs EJ, Lee S, et al. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers. Br J Clin Pharmacol.2021.

**16.** Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med.2021;385(7):595-608.

**17.** Delany-Moretlwe S, J. H, Bock P, et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. HIV R4P (HIV Research for Prevention)2021.

**18.** Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis.2021.

**19.** Han K. BM, Patel P., Margolis D., Spreen W., Moore K.P., Ford, S.L. . 1532. Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1-Infected Subjects. 2019;6(Suppl 2):S558. Published 2019 Oct 23. doi:10.1093/ofid/ofz360.1396. Open Forum Infectious Diseases.2019;2019;6:S558.

**20.** Han K BM, Lovern M, Paul P, Xiong Y, Spreen W, Moore K, Ford SL. Population pharmacokinetics of cabotegravir in adult healthy subjects and HIV-1 infected patients following administration of oral tablet and long acting intramuscular injection. American Conference on Pharmacometrics. Orlando, FL, USA.2019.

**21.** Han K PP, Baker M, Margolis D, Spreen W, Rhinehart A, Landovitz R, Ford S. Cabotegravir (CAB) Long-acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-infected Adults. Research for Prevention. Madrid, Spain2018.

**22.** Han K BM, Spreen W, Ford S. Cabotegravir Population Pharmacokinetic (PPK) Simulation to Inform Q2M Strategies Following Dosing Interruption. Conference on Retroviruses and Opportunistic Infections (CROI). Virtual2021.

**23.** Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol.2013;2:e38.

**24.** Gibaldi M, Perrier D. Pharmacokinetics / Milo Gibaldi, Donald Perrier. 2nd ed. rev. and expanded. ed. New York: M. Dekker; 1982.

**25.** Han K, Patel, P., Baker M., Margolis D., Spreen W., Ford, S. Population Pharmacokinetics of Cabotegravir in Healthy Adult Subjects and HIV-1 Infected Patients Following Administration of Oral Tablet and Long-Acting Intramuscular Injection. 22nd International AIDS Conference. Amsterdam, The Netherlands2018.


**26.** Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry.2009;33(6):1022-1031.


**27.** Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs.2011;25(10):829-845.

**28.** Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet.2009;48(9):585-600.

**Figures and Tables**

**Figure 1. Visualization of the concentration: time curves for CAB-LA, by sex at birth**






\*Above panel: Cohort 1 (800mg IM q12 weeks); Below panel: Cohort 2 (600mg IM q8 weeks)


Shape

Description automatically generated with medium confidence

**Figure 2. Schema of pharmacokinetic model for long-acting injectable cabotegravir**

**Figure 3. Goodness-of-fit plots for the final model**





**B**

**A**

**Figure 4. A. Covariate relationships between body weight and apparent clearance (CL/F); B. Covariate relationship between sex and first-order absorption rate**

**Table 1. Demographics of HPTN 077 Participants**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Cohort 1 (n=82)** | **Cohort 2 (n=69)** | **Total Cohort (n=151)** | **Data used for modeling (n=133)** |
| **Cabotegravir dosing1** | **800 mg IM q 12 wk** | **600 mg IM q 8 wk** |  |  |
| Age (yrs) at Enrollment, median (IQR) | 29.5 (24,41) | 30 (23,36) | 30 (24,39) | 29 (24,38) |
| BMI (kg/m2) at Entry, median (IQR) | 27.4 (24.1,32.6) | 25.7 (22.0,32.0) | 26.8 (23.2,32.3) | 26.6 (23.0,32.8) |
| Weight (kg), median (IQR) | 78.0 (67.6,94.3) | 72.0 (60.2,86.2) | 74.7 (62.15,91.85) | 74.7 (61.0,91.4) |
| Sex at birth2, n (%) |  |  |  |  |
| Female | 54 (66%) | 46 (67%) | 100 (66%) | 89 (67%) |
| Male | 28 (34%) | 23 (33%) | 51 (34%) | 44 (33%) |
| Race, n (%) |  |  |  |  |
| Non-Hispanic white | 29 (35%) | 13 (19%) | 42 (28%) | 36 (27%) |
| Non-Hispanic black | 31 (38%) | 33 (48%) | 64 (42%) | 55 (41%) |
| Latino | 19 (23%) | 17 (25%) | 36 (24%) | 35 (26%) |
| Non-Hispanic Asian | 0 (0%) | 3 (4%) | 3 (2%) | 2 (2%) |
| Non-Hispanic mixed/other | 3 (4%) | 3 (4%) | 6 (4%) | 5 (4%) |

1Cohort 1 received 3 total injections with no load; Cohort 2 received 5 total injections—the first 2 separated by 4 weeks as an initial load, and the last 3 separated by 8 weeks. 2 There were 6 transgender men (TGM) and 1 transgender woman (TGW) in the HPTN 077 study, who were categorized according to sex at birth; that is, TGW with the individuals born male, and TGM with the individuals born female.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Change in OFV4 |  | -23.3 | -24.435 | -36.029 | -321.428 |
| OFV | 25420 | 25396.6 | 25372.2 | 25336.17 | 25014.74 |
| BSV | Ka, CL, V2 | Ka, CL, V2, V3, Q | Ka, CL, V2, V3, Q | Ka, CL, V2, V3, Q | Ka, CL, V2, V3, Q |
| Model | 1 compartment, First-order absorption, Combined RUV | 2 compartment, First-order absorption, Combined RUV | 2 compartment, First-order absorption, Combined RUV, WT on CL (fixed=0.75) | 2 compartment, First-order absorption, Combined RUV, WT on CL (fixed=0.75), SEX on Ka | 2 compartment, First-order absorption, Combined RUV, WT on CL (fixed=0.75), SEX on Ka, BOV on Ka |
|  | 1 | 2 | 3 | 4 | 5 |

3 RUV= residual unexplained variability; BSV= between subject variability; OFV= objective function value; WT= weight; BOV= between occasion variability

4Compaired with immediately previous model

**Table 2. Model building steps3**

**Table 3. Final estimates of long-acting injectable Cabotegravir pharmacokinetic parameters, between subject variability, and residual variability2**

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | Estimate | RSE% | Shrinkage% |
| Ka(Female)(1/h) | 0.0003 | 8 |  |
| Ka(Male)(1/h) | 0.0005 | 6 |  |
| CL(L/h) | 0.148 | 2 |  |
| V2(L) | 7.84 | 3 |  |
| V3(L) | 6.99 | 6 |  |
| Q(L/h) | 0.225 | 10 |  |
| BOV on Ka | 38.5% | 4 |  |
| BSV on Ka | 82.8% | 11 | 32 |
| BSV on CL | 21.6% | 8 | 9 |
| BSV on V2 | 154.6% | 15 | 43 |
| BSV on V3 | 231.1% | 20 | 49 |
| BSV on Q | 69.6% | 86 | 85 |
| σ1(prop) | 26.3% | 2 |  |
| σ2(add (ng/mL)) | 6.8 | 4 |  |

2 Ka= absorption rate constant; CL= clearance; V2= volume of distribution of theCentral compartment; V3= volume of distribution of the Peripheral compartment; Q=intercompartmental clearance; BOV= between-occasion variability; BSV= between-subject variability; σ1=proportional residual error; σ2= additive residual error; RSE= relative standard error